Articles Authored by Caroline Hopkins
EGFR-Mutant NSCLC Patients See Similar Survival in Upfront Tagrisso Versus Sequential Treatment
A new analysis from the Phase II APPLE trial showed minimal differences in overall survival, though the newer generation TKI significantly reduced brain metastases.
Astellas Bullish on Zolbetuximab's Prospects in Gastric Cancer After Two Positive Phase III Readouts
The firm will submit data from the GLOW and SPOTLIGHT studies to regulators and seek approval for zolbetuximab plus chemo in CLDN18.2-positive HER2-negative advanced gastric cancer.
Researchers in Australia, Germany, and the US are in the early stages of developing a prostate cancer radiopharmaceutical they say could be manufactured in-house via a desktop machine.
Next-Gen Cell Therapies Bedeviled by Regulatory Murkiness on Product Characterization, Manufacturing
At a recent Friends of Cancer Research meeting, drugmakers and regulators said communication has improved on cell therapy development programs but acknowledged persistent challenges.
Patients Are Dying Waiting for Pluvicto, but Novartis Can't Make More Pending Facility Approval
Novartis has admitted it underestimated demand for the radiopharmaceutical, though the FDA's approval of a US-based manufacturing facility may provide some relief by summer.
Drugmakers Pushing Frontline PARP Inhibitor Combos for All mCRPC Patients Amid Oncologists' Concerns
The makers of several PARP inhibitors shared data they said support using these drugs with anti-androgen therapy in all advanced prostate cancer patients, but oncologists want more biomarker data.
The firm is evaluating if an oral pill containing the bacteria Akkermansia can improve immunotherapy responses among lung and kidney cancer patients.
The drugmaker is expecting Trodelvy sales to increase even more this year if the FDA approves a broader breast cancer indication later this month.
Merck's Keytruda Sales Increase 19 Percent in Q4; Lynparza Reaches Blockbuster Status in 2022
During an earnings call, the company's executives detailed strategies for replacing revenue from its bestselling drug Keytruda, slated to lose market exclusivity in coming years.
The Swiss drugmaker's CDK4/6 inhibitor Kisqali saw significant sales growth, as did newly launched therapies Pluvicto and Scemblix.